1. Home
  2. WINA vs IMNM Comparison

WINA vs IMNM Comparison

Compare WINA & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Winmark Corporation

WINA

Winmark Corporation

HOLD

Current Price

$404.96

Market Cap

1.5B

ML Signal

HOLD

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$21.46

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WINA
IMNM
Founded
1988
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.8B
IPO Year
1993
2020

Fundamental Metrics

Financial Performance
Metric
WINA
IMNM
Price
$404.96
$21.46
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
$31.44
AVG Volume (30 Days)
82.0K
3.0M
Earning Date
02-18-2026
11-06-2025
Dividend Yield
2.80%
N/A
EPS Growth
2.56
N/A
EPS
11.21
N/A
Revenue
$84,517,400.00
$9,679,000.00
Revenue This Year
$7.05
N/A
Revenue Next Year
$3.60
$11.53
P/E Ratio
$36.11
N/A
Revenue Growth
3.35
N/A
52 Week Low
$295.79
$5.15
52 Week High
$527.37
$25.30

Technical Indicators

Market Signals
Indicator
WINA
IMNM
Relative Strength Index (RSI) 41.39 56.28
Support Level $398.07 $21.00
Resistance Level $420.04 $22.57
Average True Range (ATR) 15.41 1.41
MACD -2.09 -0.11
Stochastic Oscillator 12.06 40.99

Price Performance

Historical Comparison
WINA
IMNM

About WINA Winmark Corporation

Winmark Corp is a franchisor of value-oriented retail store concepts that buy, sell, and trade gently used merchandise. The company has one reportable segment including Franchising and one non-reportable segment Leasing. The franchising segment franchises value-oriented retail store that buys, sell, trade, and consign merchandise as well as provide strategic consulting services relating to franchising. The leasing segment includes middle-market equipment leasing business and small-ticket financing business. It generates a majority of its revenue from the Franchising segment.

About IMNM Immunome Inc.

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.

Share on Social Networks: